Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Nab-paclitaxel + Oblimersen + Temozolomide
Indication/Tumor Type melanoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown melanoma not applicable Nab-paclitaxel + Oblimersen + Temozolomide Phase I Actionable In a Phase I trial, treatment with the combination of Genasense (oblimersen), Temodar (temozolomide), and Abraxane (nab-paclitaxel) resulted in an objective response rate of 40.6% (13/32) and disease control rate of 75% (24/32) in patients with advanced melanoma (PMID: 23064957). 23064957
PubMed Id Reference Title Details
(23064957) Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Full reference...